ANTX Stock Overview
A biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
AN2 Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.21 |
| 52 Week High | US$3.07 |
| 52 Week Low | US$0.87 |
| Beta | 0.0055 |
| 1 Month Change | -3.97% |
| 3 Month Change | 8.04% |
| 1 Year Change | -46.70% |
| 3 Year Change | -88.37% |
| 5 Year Change | n/a |
| Change since IPO | -92.14% |
Recent News & Updates
Recent updates
We're Keeping An Eye On AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate
Nov 21
Is AN2 Therapeutics (NASDAQ:ANTX) In A Good Position To Invest In Growth?
Jul 04Here's Why We're Not Too Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation
Mar 23AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans
Dec 05AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans
Aug 20We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth
May 09We're Not Very Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate
Feb 03We're Hopeful That AN2 Therapeutics (NASDAQ:ANTX) Will Use Its Cash Wisely
Oct 21AN2 Therapeutics secures $17.8M contract from NIH
Sep 29We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth
Jul 01Shareholder Returns
| ANTX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.8% | 1.4% | 5.3% |
| 1Y | -46.7% | -9.8% | 11.9% |
Return vs Industry: ANTX underperformed the US Pharmaceuticals industry which returned -9.8% over the past year.
Return vs Market: ANTX underperformed the US Market which returned 11.9% over the past year.
Price Volatility
| ANTX volatility | |
|---|---|
| ANTX Average Weekly Movement | 7.1% |
| Pharmaceuticals Industry Average Movement | 11.2% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: ANTX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ANTX's weekly volatility has decreased from 13% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 22 | Eric Easom | www.an2therapeutics.com |
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company’s initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform.
AN2 Therapeutics, Inc. Fundamentals Summary
| ANTX fundamental statistics | |
|---|---|
| Market cap | US$36.42m |
| Earnings (TTM) | -US$45.35m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs ANTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$45.35m |
| Earnings | -US$45.35m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.51 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ANTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/18 04:52 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AN2 Therapeutics, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Douglas Buchanan | Citizens JMP Securities, LLC |
| Liisa Bayko | Evercore ISI |
| Joseph Schwartz | Leerink Partners LLC |